Michael S. Perry, Hon BSc, DVM, PhD, is a Venture Partner with Bay City Capital and has been with the firm since 2005.  Dr. Perry is also President and Chief Medical Officer of Poniard Pharmaceuticals, a Bay City Capital portfolio company.  Dr. Perry has over 20 years of experience as a C-level executive in the biopharma industry and has been materially involved in the filing of over 50 INDs and over 30 NDAs/BLAs across the globe.  His previous roles include Chief Development Officer of VIA Pharmaceuticals (VIAP) and Founder and Chief Executive Officer of Extropy Pharmaceuticals.  He was also Chief Executive Officer of Pharsight (PHST), SyStemix and Genetic Therapy, and served as a director on each of the companies' boards.  Prior to these positions, Dr. Perry was Global Head of R&D for Baxter BioScience, Vice President  of Novartis Pharma, and Vice President of Syntex Corporation.  He currently serves as a member of the board of directors of Targeted Genetics (TGEN).  Dr. Perry holds an Honors BSc in Engineering/Physics from the University of Guelph, a DVM from the Ontario Venterinary College, and a PhD in Biomedical Pharmacology from the University of Guelph  He is a Fellow of the royal College of Veterinary Surgeons and is also a graduate of the Executive International Management Program at Harvard Business School.